What is the iPRS™ test for prostate cancer?

The Prostate Cancer iPRS™ test combines whole-genome insights with key clinical factors to estimate an individual’s risk of developing prostate cancer. All reports will communicate risk in terms of integrated lifetime risk and relative risk of developing prostate cancer. For patients ages 40-70, an integrated 10-year risk will also be reported. By integrating millions of genetic markers with clinical information, the test provides a more complete and accurate picture of personal prostate cancer risk than models based on a single factor alone.